ACTU
Price
$0.52
Change
-$0.04 (-7.14%)
Updated
Oct 22 closing price
Capitalization
12.4M
21 days until earnings call
Intraday BUY SELL Signals
RARE
Price
$15.95
Change
+$0.03 (+0.19%)
Updated
Oct 22 closing price
Capitalization
1.57B
12 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACTU vs RARE

ACTU vs RARE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ACTU vs. RARE commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACTU is a StrongBuy and RARE is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ACTU with price predictions
Oct 22, 2026

ACTU's RSI Indicator climbs out of oversold territory

The RSI Oscillator for ACTU moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 21 of the 23 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 22 of 24 cases where ACTU's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for ACTU just turned positive on October 19, 2026. Looking at past instances where ACTU's MACD turned positive, the stock continued to rise in 15 of 17 cases over the following month. The odds of a continued upward trend are 88%.

Following a +39.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACTU advanced for three days, in 87 of 97 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

ACTU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACTU as a result. In 37 of 41 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACTU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for ACTU entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.532) is normal, around the industry mean (2.973). P/E Ratio (-0.593) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. ACTU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACTU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for RARE with price predictions
Oct 22, 2026

Momentum Indicator for RARE turns positive, indicating new upward trend

RARE saw its Momentum Indicator move above the 0 level on October 19, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 73 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RARE's RSI Indicator exited the oversold zone, 26 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.

The Moving Average Convergence Divergence (MACD) for RARE just turned positive on September 22, 2026. Looking at past instances where RARE's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.

Following a +10.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where RARE advanced for three days, in 220 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

The Aroon Indicator entered an Uptrend today. In 152 of 226 cases where RARE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RARE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

RARE broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.404) is normal, around the industry mean (2.973). P/E Ratio (-2.736) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1.809) is also within normal values, averaging (438.009).

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. RARE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
RARE: Fundamental Ratings
RARE
OUTLOOK RATING
1..100
7
VALUATION
overvalued / fair valued / undervalued
1..100
17
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
11
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACTURARE
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
78%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
88%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
72%
Advances
ODDS (%)
Bullish Trend 7 days ago
90%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 9 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
67%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ACTU: $0.56 vs. RARE: $15.95)
Brand notoriety: ACTU and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACTU: 57% vs. RARE: 42%
Market capitalization -- ACTU: $12.4M vs. RARE: $1.57B
ACTU [@Biotechnology] is valued at $12.4M. RARE’s [@Biotechnology] market capitalization is $1.57B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACTU’s FA Score shows that 0 FA rating(s) are green while RARE’s FA Score has 2 green FA rating(s).

  • ACTU’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 2 green, 3 red.
According to our system of comparison, RARE is a better buy in the long-term than ACTU.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACTU’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 5 bullish TA indicator(s).

  • ACTU’s TA Score: 5 bullish, 3 bearish.
  • RARE’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both ACTU and RARE are a good buy in the short-term.

Price Growth

ACTU (@Biotechnology) experienced а +29.48% price change this week, while RARE (@Biotechnology) price change was +5.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

ACTU is expected to report earnings on Nov 12, 2026.

RARE is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ACTU
Daily Signal:
Gain/Loss:
RARE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ACTU and

Correlation & Price change

A.I.dvisor tells us that ACTU and TBPH have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACTU and TBPH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACTU
1D Price
Change %
ACTU100%
-8.18%
TBPH - ACTU
28%
Poorly correlated
N/A
PDSB - ACTU
27%
Poorly correlated
-6.45%
DNA - ACTU
25%
Poorly correlated
-3.00%
ABEO - ACTU
24%
Poorly correlated
-0.89%
RARE - ACTU
24%
Poorly correlated
+0.19%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GD350.796.08
+1.76%
General Dynamics Corp
LSTR169.39-1.89
-1.10%
Landstar System
RDWR29.78-0.50
-1.65%
Radware Ltd
AERT5.62-0.28
-4.75%
Aeries Technology Inc.
QNC1.16-0.06
-4.92%
Quantum eMotion Corp.